




The relative strengths and weaknesses of Pharmacyclics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pharmacyclics INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Pharmacyclics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 364%, being 110% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	1,015,559
Cost of Goods Sold	0
Intangible Assets	8,730
Liabilities, Current	194,236
Liabilities, Non-Current	1,821
Other Assets	3,342
Other Compr. Net Income	0
Other Expenses	303,257
Other Liabilities	34,885
Other Net Income	-374
Other Revenues	730,169
Property and Equipment	32,476
Research and Development	172,459
Selling, General and Administrative Expense	167,955

Output Variable	Value in 1000 USD
Assets	1,060,107
Liabilities	230,942
Expenses	643,671
Revenues	730,169
Stockholders Equity	829,165
Net Income	86,124
Comprehensive Net Income	86,124
BaseVar	1,332,632
ECR before LimitedLiability	293%
Economic Capital Ratio	364%